Kelsey K. Baker

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker et autres

Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility …

us, gb (code pays fourni par la source)

Supplemental Table 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 1: Primer/probe sequences used in the duplex mEVL assay

Supplemental Figure 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Figure 1. Flowchart of patient selection. * Subjects with hereditary conditions or inflammatory bowel disease (IBD) were excluded. A flowchart showing the selection process for the subjects included in the studies is shown. The primary exclusion criteria that affected subject selection …

Supplemental Figure 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Figure 4: Methylation levels of normal colon for patients with no history of adenoma or cancer after initial amongst those at least 4 years of follow-up (left group) and levels for patients with an adenoma or colorectal cancer detected after initial …

Supplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 2: Summary patient characteristics for Comparison Set 1

Supplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 4: Summary patient characteristics for Comparison Set 3

Supplemental Table 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 3: Summary patient characteristics for Comparison Set 2

Supplemental Table 5 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 5: Summary statistics for methylated EVL measurements in Comparison Set 1

Supplemental Table 6 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 6: Summary statistics for methylated EVL measurements in Comparison Set 2

Supplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Table 7: Summary statistics for methylated EVL measurements in Comparison Set 3

Supplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Figure 3: EVL methylation levels of normal colon for patients with no history of adenoma or cancer after initial colonoscopy (left group) and for levels patients with an adenoma or colorectal cancer detected after initial (middle group). Patients with no follow-up …

Supplemental Figure 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman et autres

Supplemental Figure 2: Methylation levels of normal colon mucosa in patients with no history of adenoma or cancer ever (group on left) and levels for patients with a history of adenoma(s) or colorectal cancer at initial or a follow-up colonoscopy (group on …